Windshift,
I think Deborah is so close to being done. She & Bionomics are coming up on 2 decades & what is there to show for it.
She's claiming all kinds of new therapies as the way forward - that is unacceptable. It's too far out.
If she can't get an agitation medication to market by 2020 she may as well resign now.
If it's someone else as CEO my opinion is they don't cap raise they just sell what's there - everything. In a much tighter timeframe than Deborah has had to get rid of the 2 oncology medications.
(When Deborah goes my sentiment changes to Buy. She is just proving to be an absolute barry on the backfoot.)
Baseless
